Chew Sin-Chi, Lim Joanne, Singh Onkar, Chen Xiangai, Tan Eng-Huat, Lee Edmund-J D, Chowbay Balram
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 10 Medical Drive, Singapore, Singapore, 117597.
Eur J Clin Pharmacol. 2014 Feb;70(2):155-66. doi: 10.1007/s00228-013-1596-3. Epub 2013 Nov 6.
This exploratory study was aimed at elucidating the pharmacogenetics of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) and their implications on docetaxel pharmacokinetics and pharmacodynamics in local Chinese nasopharyngeal cancer patients.
A total of 59 single nucleotide polymorphisms (SNPs), including tag-SNPs and functionally relevant SNPs of the genes encoding these regulatory nuclear receptors (PXR/NR1I2, CAR/NR1I3, RXRα/NR2B1 and HNF4α/NR2A1), were profiled in the patients enrolled in our study by direct sequencing (N = 50). The generalized linear model was employed to estimate the haplotypic effects on the pharmacokinetics and pharmacodynamics of the patients.
The pharmacokinetic profiles of docetaxel in these patients were characterized by marked interindividual variability, with approximately four- to sixfold variations observed in Cmax, AUC0-∞ and CL. Individual SNP association tests revealed that polymorphisms in NR2B1 and NR2A1 were significantly correlated with altered docetaxel pharmacokinetics. Subsequent haplotype association analysis identified the NR2B1 LD block 2 AG haplotype [*+4458G>A(rs3132291) and *+4988A>G(rs4842198)] to be significantly associated with altered pharmacokinetics, in which patients carrying two copies of the AG haplotype had approximately a 20 % decreased Cmax and AUC0-∞ and a 21 % increased CL compared to those who carried only one copy or no copies of the haplotype. A number of SNPs in NR1I2, NR1I3, NR2B1 and NR2A1 were also associated with a significant decrease in blood counts from baseline. No haplotype was found to exert any effects on the pharmacodynamics parameters.
The present exploratory study identified several SNPs in the genes encoding regulatory nuclear receptors which may account for the interpatient variability in docetaxel pharmacokinetics and pharmacodynamics. These findings highlight the important role of regulatory nuclear receptors on the disposition of docetaxel.
本探索性研究旨在阐明调节性核受体(PXR、CAR、RXRα和HNF4α)的药物遗传学及其对中国局部鼻咽癌患者多西他赛药代动力学和药效学的影响。
通过直接测序(N = 50)对参与本研究的患者中总共59个单核苷酸多态性(SNP)进行了分析,这些SNP包括编码这些调节性核受体(PXR/NR1I2、CAR/NR1I3、RXRα/NR2B1和HNF4α/NR2A1)的基因的标签SNP和功能相关SNP。采用广义线性模型来估计单倍型对患者药代动力学和药效学的影响。
这些患者中多西他赛的药代动力学特征表现为显著的个体间差异,在Cmax、AUC0-∞和CL方面观察到约四至六倍的变化。个体SNP关联测试显示,NR2B1和NR2A1中的多态性与多西他赛药代动力学改变显著相关。随后的单倍型关联分析确定NR2B1 LD模块2 AG单倍型[+4458G>A(rs3132291)和+4988A>G(rs4842198)]与药代动力学改变显著相关,其中携带两份AG单倍型的患者与仅携带一份或不携带该单倍型的患者相比,Cmax和AUC0-∞降低约20%,CL增加21%。NR1I2、NR1I3、NR2B1和NR2A1中的一些SNP也与血细胞计数从基线显著下降有关。未发现任何单倍型对药效学参数有影响。
本探索性研究在编码调节性核受体的基因中鉴定出了几个SNP,这些SNP可能解释了患者间多西他赛药代动力学和药效学的变异性。这些发现突出了调节性核受体在多西他赛处置中的重要作用。